We delivered a full suite of non–COVID-19 products, including Horizon Scans, Reference Lists, Reimbursement Recommendations, and Health Technology Reviews.

We moved forward with our efforts to comply with the Accessibility for Ontarians with Disabilities Act.

We implemented new technologies to modernize our Human Resource and Finance departments.

We launched the Canadian Journal of Health Technologies.

We contributed to the development of a national strategy for high-cost drugs for rare diseases.

We developed a framework for, and launched, our first condition-level review.

We updated and aligned our Common Drug Review, pan-Canadian Oncology Drug Review, and Interim Plasma Protein Product Review processes.